Shionogi and Tetra expand partnership ahead of Alzheimer's t...

Shionogi has expanded its partnership with its Alzheimer’s drug development partner Tetra Therapeutics, giving an option for a buyout of the US biotech ahead of a key trial milestone.

Pharma staff told to work at home as Biogen deals with coron...

The coronavirus has begun to affect day-to-day operations at pharma companies, with Biogen dealing with an outbreak linked to a management meeting at an affected hotel, and others telling s

Biogen and Sangamo work on Parkinson's and Alzheimer's gene ...

Biogen and Sangamo have begun a collaboration to develop gene regulation therapies for neurological diseases including Parkinson’s and Alzheimer’s in a collaboration worth more than $2.7 bi

Warren Buffet shocks Wall Street with Biogen gamble

Biogen is trying to resurrect two failed trials of its Alzheimer’s drug aducanumab – and superstar investor Warren Buffet thinks the volatile stock is worth gambling on as the company prepa

Is Tecfidera’s patent win a pyrrhic victory for Biogen?

Shares in Biogen jumped last week after the company successfully defended its blockbuster MS drug Tecfidera from a patent challenge – but will the boost mean much when the company still fac

Biogen claims victory in patent dispute with Mylan over MS d...